KOSDAQBiotech & Pharma471820

Cellromax Science

₩3,615 0.00%2026-11-18 close
Market Cap
₩40.9B
Turnover
₩6,753,700
Volume
1.9K
Shares out.
11.3M
PER
12.9×
PBR
0.9×
EPS
₩281
Dividend Yield
5.11%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters · Dividend yield is based on ₩185 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit recovery in 2026 follows steep 2025 decline

Operating profit has recovered from its fourth-quarter 2025 low, but full-year 2025 operating profit fell 48.5% from the prior year, so the durability of that recovery is still to be confirmed.

  1. 1

    Revenue reached KRW 22.2 billion in 2025, up 2.6% year on year, a sharp slowdown from the 12.0% gain in 2024.

  2. 2

    Operating profit fell to KRW 2.84 billion in 2025, down 48.5%, and the operating margin dropped from 25.4% to 12.8%.

  3. 3

    Operating profit rose to KRW 981 million in the second quarter of 2026, up 181.6% quarter on quarter, and KRW 826 million in the third quarter, up 12.1% year on year, while third-quarter revenue fell 7.5% year on year.

  4. 4

    The debt-to-equity ratio was 8.5% at the end of 2025, and total equity of KRW 46.9 billion was entirely attributable to owners of the parent.

  5. 5

    Shareholder-return disclosures continued in 2026, including quarterly dividend record-date notices and a treasury share cancellation.

02

Business structure

Cellromax Science was founded in October 2014 and, according to its company profile, supplies health functional foods, cosmetics and over-the-counter drugs whose formulations are designed by licensed pharmacists.

Its business profile lists the industry as health functional food manufacturing, and the company listed on KOSDAQ on December 13, 2024. Revenue scale is best gauged from the reported total revenue trend.

Media reports from April 2026 said the company had launched two Doraji (platycodon) products for spring bronchial care.

Its company history includes a January 2023 patent for a composition for preventing or treating osteoporosis in women based on Angelica, Peony and Saffron extracts, and a July 2022 patent for an immune-boosting composition based on a plant powder.

The company emphasizes a network of member pharmacies as its sales channel, so demand shifts in that channel can feed quickly into revenue. In September 2025 it acquired a 17.17% equity stake in a Korean bio company.

In April and May 2026 it set up subsidiaries in Beijing and Asia, widening its overseas consolidated group. The product line centers on health functional foods but also spans cosmetics and OTC drugs. Its core customers appear to be individual consumers and member pharmacies.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.3B₩700M13.8%
2025Q4₩4.5B₩86,388,4941.9%
2026Q1₩4.7B₩300M7.4%
2026Q2₩5.1B₩1B19.3%
2026Q3₩4.9B₩800M16.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩19.3B₩4.6B₩4.5B23.9%14.9%9.0%
2024₩21.6B₩5.5B₩3.8B25.4%8.6%10.3%
2025₩22.2B₩2.8B—12.8%—8.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a reported basis, revenue rose from KRW 19.3 billion in 2023 to KRW 21.6 billion in 2024 (up 12.0% year on year) and reached KRW 22.2 billion in 2025 (up 2.6%).

Revenue grew in both 2024 and 2025, two consecutive years of growth on the reported figures, and 2025 was the largest year of the 2023 to 2025 span while 2023 was the smallest.

Operating profit went from KRW 4.62 billion in 2023 to KRW 5.5 billion in 2024 (up 19.1%) and then to KRW 2.84 billion in 2025 (down 48.5%), with 2024 the largest year and 2025 the smallest. The operating margin moved from 23.9% to 25.4% and then to 12.8%.

Because revenue still rose in 2025 while the margin fell sharply, the pressure appears to have come from costs rather than from sales slowing alone, and the line-item drivers belong in the full-year business report.

Profit attributable to owners of the parent fell from KRW 4.5 billion in 2023 to KRW 3.82 billion in 2024 (down 15.2%), and net profit including non-controlling interests was reported at the same two amounts for those years.

Operating cash flow declined from KRW 5.07 billion in 2023 and KRW 6.29 billion in 2024 to KRW 1.79 billion in 2025, moving in the same direction as operating profit. Quarterly operating profit bottomed at KRW 86.39 million in the fourth quarter of 2025, down 88.3% from KRW 737 million in the third quarter of 2025.

It then recovered to KRW 348 million in the first quarter of 2026 (up 303.3%) and KRW 981 million in the second quarter (up 181.6%). The first-quarter figure remained below the 2025 third-quarter level, while the second quarter exceeded it.

Third-quarter 2026 revenue of KRW 4.93 billion fell 3.0% quarter on quarter and 7.5% year on year, yet operating profit of KRW 826 million rose 12.1% year on year, so profit grew even as sales declined.

05

Industry analysis

Health functional foods, cosmetics and OTC drugs, the company's core categories, each operate under different regulatory frameworks.

In health functional foods, functional ingredients and labeling rules shape product competitiveness, while OTC drugs fall under pharmaceutical affairs regulation that tightly controls sales channels.

As a result, even a company with ingredient patents and a pharmacy network may see its pace of product expansion shaped by the regulatory environment.

Product lines are organized around function, such as bronchial care, immunity and bone health, so competition tends to turn on ingredient differentiation and distribution reach.

The exchange classifies the company under biopharma and pharmaceuticals, but its own profile centers on health functional food manufacturing, so its revenue structure and earnings model differ from those of listed drug developers.

At KRW 22.2 billion of 2025 revenue, the company is small next to large listed biopharma names, and its profit depends heavily on product margins. The Beijing and Asia subsidiaries can be read as an attempt to take a domestic channel-led business overseas.

Industry cycle data and market-size figures are not reflected here, so the industry read is best framed around how the company's reported results line up with regulatory and channel conditions.

06

Outlook

The most concrete near-term development the company has announced is overseas expansion.

The Beijing subsidiary set up in April 2026 and the Asia subsidiary set up in May 2026 widen the consolidated group, and when and how much overseas revenue shows up in results will be visible in the consolidation notes of the business report.

On products, two Doraji (platycodon) bronchial-care items were launched in spring 2026, and whether seasonal products repeat their sales will shape revenue.

On shareholder returns, quarterly dividend record dates were announced for March 31 and June 30, 2026, and a quarterly dividend decision followed in October 2026, so the quarterly dividend cadence continues.

A treasury share cancellation of 278,324 shares with a scheduled date of March 4, 2026 and an employee bonus disposal of 34,461 treasury shares on April 1, 2026 both change the share count.

Whether the 2025 profit decline was temporary or structural can be gauged by whether the full-year 2026 operating margin returns toward the 25.4% of 2024.

The gap between the 2026 first-quarter operating profit of KRW 348 million and the second-quarter figure of KRW 981 million will show whether the recovery is seasonal or cost-driven. Because third-quarter 2026 revenue fell year on year, whether sales growth follows the profit recovery is the next point to confirm.

07

Valuation

PER
12.9×
PBR
0.9×
ROE
7.0%
EPS
₩281
BPS
₩4,165
Dividend per share
₩185

The price-to-book ratio sits below 1x, which means the shares trade below the book value of the company's net assets. Total equity at the end of 2025 was KRW 46.9 billion, all attributable to owners of the parent, and total liabilities were KRW 3.99 billion, so the balance sheet carries a light debt load.

The price-to-earnings ratio is calculated on 2025 earnings, when operating profit fell 48.5%, so its reading may change once full-year 2026 results are filed around March 2027. Compared with 2024, when the operating margin was 25.4%, the same multiple means something different depending on how far profit has recovered.

The dividend yield reading depends on whether quarterly dividend decisions continue through the end of the year. A discount to net assets and a period of falling profit appear together here, so the two readings are best taken alongside each other. This comparison stays with factual relationships and does not offer a view on the direction of the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly operating profit recovery

Second-quarter 2026 operating profit of KRW 981 million rose 181.6% from the prior quarter and exceeded the KRW 737 million of the third quarter of 2025. Third-quarter 2026 operating profit of KRW 826 million was up 12.1% year on year. Compared with the KRW 86.39 million low of the fourth quarter of 2025, the rebound is pronounced.

Low debt burden

Total liabilities at the end of 2025 were KRW 3.99 billion, and the debt-to-equity ratio was 8.5%, down from 10.3% in 2024. All KRW 46.9 billion of equity is attributable to owners of the parent. The light borrowing load reads as a cushion in a year when profit declined.

Quarterly dividends and shareholder returns

The company announced quarterly dividend record dates of March 31 and June 30, 2026. A quarterly dividend decision was disclosed in October 2026. A cancellation of 278,324 treasury common shares, scheduled for March 4, 2026, was also decided.

09

Bear factors

Sharp profit drop in 2025

Operating profit fell 48.5% to KRW 2.84 billion in 2025. The operating margin dropped from 25.4% in 2024 to 12.8%, roughly half. Revenue still rose 2.6% that year, so the decline reads as a cost-side burden.

Slowing growth and a third-quarter decline

Revenue growth slowed to 2.6% in 2025 from 12.0% in 2024. Third-quarter 2026 revenue of KRW 4.93 billion fell 7.5% year on year and 3.0% quarter on quarter. Whether profit recovery continues on a flat sales base is the core of the bearish case.

Weaker cash generation

Operating cash flow fell from KRW 5.07 billion in 2023 and KRW 6.29 billion in 2024 to KRW 1.79 billion in 2025. Profit attributable to owners of the parent fell 15.2% in 2024, from KRW 4.5 billion to KRW 3.82 billion. The weaker cash generation is best read alongside the expansion into overseas subsidiaries.

10

Risk factors

Product and channel concentration

With health functional foods, cosmetics and OTC drugs as its core, demand shifts in specific products or in the pharmacy channel pass quickly into revenue. The year-on-year decline in third-quarter 2026 sales may relate to such demand swings. Whether the seasonal Doraji products sell again could drive the revenue path.

Cost of overseas expansion

The Beijing subsidiary in April 2026 and the Asia subsidiary in May 2026 widened the overseas footprint. New entities usually carry early staffing and facility costs, and monetization may come later.

Whether overseas profit and loss is disclosed separately from domestic operations is a point to check in the business report.

Small-cap share count changes

As a small-cap with market value in the hundreds of billions of won, the shares can show sharp price swings when trading volume is thin. Employee bonus shares of 34,461 treasury shares were disposed of on April 1, 2026, and a March 2026 cancellation adjusted the issued share count. Share count changes also affect per-share metric readings.

11

What to watch next

  1. End of December 2026

    Whether a dividend record-date notice is issued and its size. Comparing with the March 31 and June 30, 2026 record dates shows whether quarterly dividends continue through year-end.

  2. Mid-March 2027

    The notice and agenda for the annual general meeting. In 2026 the notice came on March 14 and the meeting on March 31, so whether dividend or articles items appear is the point to check.

  3. Late March 2027

    Filing of the 2026 annual business report. Whether the operating margin recovers from 12.8% in 2025, how it compares with 25.4% in 2024, and whether overseas subsidiary results are disclosed separately are the points to check.

  4. Mid-May 2027

    The first-quarter 2027 quarterly report. Whether operating profit holds above the KRW 348 million of the first quarter of 2026 and the KRW 981 million of the second quarter, and whether revenue grows year on year again, are the points to check.

12

Overall view

Cellromax Science's 2025 full-year results combined slowing revenue growth with a 48.5% fall in operating profit. Quarterly operating profit recovered from its fourth-quarter 2025 low through the second quarter of 2026.

Third-quarter 2026 revenue fell 7.5% year on year, yet operating profit rose 12.1%, pointing to an improved profit structure. On the balance sheet, a debt-to-equity ratio of 8.5% and equity fully attributable to owners of the parent provide a cushion.

However, operating cash flow fell to KRW 1.79 billion in 2025, and the 12.8% operating margin for 2025 was below the 25.4% of 2024, so a full-year return to earlier profitability is not yet confirmed. Shareholder returns have been disclosed regularly through quarterly dividend notices and treasury share cancellation.

Overseas subsidiaries and product extensions such as the Doraji products widen the business, but when they become profitable is a question for the business report.

The next points to confirm are the full-year 2026 operating margin in the business report, the dividend notice at the end of December 2026, and the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. saramin.co.kr
  2. alphasquare.co.kr
  3. news.nate.com
  4. cellromax.kr
  5. m.saramin.co.kr
  6. m.news.nate.com
  7. m.news.nate.com
  8. marketbz.com
  9. judal.co.kr
  10. judal.co.kr
  11. quiverquant.com
  12. manilatimes.net
  13. globenewswire.com
  14. stocktitan.net
  15. m.thinkpool.com
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis